PCT patent applications related to the Life Sciences sector in Australia and New Zealand and published over the last twelve months
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 November 2018)
The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.
The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.
Australian applications
Here are the 191 PCT patent applications relevant to Australia's Life Sciences sector that have published since 2 November 2017, for a publication rate of 3.6 applications per week:
- WO/2018/195601, Encapsulated nutritional and pharmaceutical compositions, Clover Corporation, 1 November 2018
- WO/2018/191794, Liquid crystalline dosage form for administering a statin, Zeenar Enterprises Pty Ltd, 25 October 2018
- WO/2018/191793, Fast disintegrating tablet, Zeenar Enterprises Pty Ltd, 25 October 2018
- WO/2018/191792, Process for preparing an oral disintegrating dosage form, Zeenar Enterprises Pty Ltd, 25 October 2018
- WO/2018/191789, Therapeutic compounds and methods, University of Tasmania, 25 October 2018
- WO/2018/191786, CD14 antagonist antibodies for treating neurodegenerative diseases, Implicit Bioscience Pty Ltd, 25 October 2018
- WO/2018/191771, Detection and treatment of congenital malformations, Victor Chang Cardiac Research Institute, 25 October 2018
- WO/2018/187849, Cold-water-dispersible chemical delivery system, Pharmako Biotechnologies Pty Ltd, 18 October 2018
- WO/2018/187845, Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelate pathway, La Trobe University, 18 October 2018
- WO/2018/186755, Novel vaccine for the prevention or treatment of an infection caused by a Herpes virus, Beagley et. al., 11 October 2018
- WO/2018/185557, Administration of antibiotic compounds for the treatment of streptococcal infections for the treatment of psoriasis, Center for Digestive Diseases, 11 October 2018
- WO/2018/185030, Androgen receptor agonists for treating type 2 inflammations, INSERM, Université Paul Sabatier Toulouse III, CNRS and Walter and Eliza Hall Institute of Medical Research, 11 October 2018
- WO/2018/184074, Method for treating a side effect of Chimeric Antigen Receptor (CAR) T cell therapy, Cynata Therapeutics, 11 October 2018
- WO/2018/184059, Compositions and methods for prophylaxis or treatment of pain, InterK Peptide Therapeutics, 11 October 2018
- WO/2018/176099, Treatment of respiratory infection with a TLR2 agonist, Ena Therapeutics Pty Ltd, 4 October 2018
- WO/2018/176098, Prophylaxis and treatment of cognitive dysfunction and decline, Florey Institute of Neuroscience and Mental Health, 4 October 2018
- WO/2018/176093, Berberine alkaloid formulations in the prevention and/or treatment of infectious disease, iRiccorgPharm Pty Ltd, 4 October 2018
- WO/2018/176079, Berberine alkaloids in the prevention and/or treatment of intestinal disease, iRiccorgPharm Pty Ltd, 4 October 2018
- WO/2018/176075, Chimeric insect-specific flaviviruses, University of Queensland, 4 October 2018
- WO/2018/170559, Combination therapy for the treatment or prevention of tumours, QBiotics Ltd, 27 September 2018
- WO/2018/170553, Complexes and uses thereof, Curtin University of Technology, 27 September 2018
- WO/2018/170547, Live vaccine strains, Pork CRC Ltd, 27 September 2018
- WO/2018/170532, Treatment method, Lilian and Burkhard Franz, 27 September 2018
- WO/2018/165752, Antibody conjugate for treating and detecting bladder cancer, University of South Australia, Central Adelaide Local Health Network and Université de Sherbrooke, 20 September 2018
- WO/2018/165720, Agents for treating or preventing viral infections and uses therefor, Implicit Bioscience Pty Ltd, 20 September 2018
- WO/2018/165718, Heterocyclic inhibitors of PCSK9, Cardio Therapeutics Pty Ltd, 20 September 2018
- WO/2018/165711, Biodegradable drug-polymer conjugate, Polyactiva Pty Ltd, 20 September 2018
- WO/2018/165710, Drug-polymer conjugate, Polyactiva Pty Ltd, 20 September 2018
- WO/2018/165708, Treatment for gingivitis, University of Melbourne, 20 September 2018
- WO/2018/165707, Complexes for treating sensitivity, University of Melbourne, 20 September 2018
- WO/2018/157190, Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis, 7 September 2018
- WO/2018/154391, CXCR2 antibodies and uses thereof, Monash University, 30 August 2018
- WO/2018/153991, Novel peptides and their use in diagnosis, Biotome Pty Ltd, 30 August 2018
- WO/2018/152592, Methods and products for reducing adhesions, University of Adelaide, 30 August 2018
- WO/2018/152584, A malaria vaccine and methods for producing same, Walter and Eliza Hall Institute of Medical Research and ExpreS2ion Biotechnologies (Denmark), 30 August 2018
- WO/2018/152572, T cells expressing chemokine receptors for treating cancer, University of Adelaide, 30 August 2018
- WO/2018/148797, A method of treatment, University of Melbourne, 23 August 2018
- WO/2018/148795, Compositions for treating acne, Botanix Pharmaceuticals, 23 August 2018
- WO/2018/148788, Method for predicting risk and rate of amyloid deposition and plaque formation, CRC For Mental Health, 23 August 2018
- WO/2018/148787, Formulations of cannabinoids for the treatment of psoriasis, Botanix Pharmaceuticals, 23 August 2018
- WO/2018/148786, Formulations of cannabinoids for the treatment of acne, Botanix Pharmaceuticals, 23 August 2018
- WO/2018/148785, Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases, Botanix Pharmaceuticals, 23 August 2018
- WO/2018/145162, Steroid saponins with anti-cancer activity, Oncology Research International Ltd, 16 August 2018
- WO/2018/145159, Terminalia ferdinandiana leaf extract and products containing extract of Terminalia ferdinandiana leaf, Rising Phoenix Industries Pty Ltd, 16 August 2018
- WO/2018/145148, Methods of treating influenza, Biotron, 16 August 2018
- WO/2018/145147, A method of treating a fibrotic condition associated with excessive collagen formation using activators of the collagenase production pathway, David Chin, 16 August 2018
- WO/2018/142318, Alpha-MSH analogues used in the treatment of Xeroderma Pigmentosum, Clinuvel Pharmaceuticals, 9 August 2018
- WO/2018/141029, Immunostimulating compositions and uses therefore, Meat & Livestock Australia, State of Queensland and US Department of Agriculture, 9 August 2018
- WO/2018/141025, Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof, Benitec Biopharma, 9 August 2018
- WO/2018/141002, Derivatives of N-cycloalkyl/heterocycloalkyl-4-(Imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents, University of South Australia, 9 August 2018
- WO/2018/138578, Compositions for the treatment of hypertension, George Institute for Global Health, 2 August 2018
- WO/2018/137002, A method of treatment, Hudson Institute of Medical Research, 2 August 2018
- WO/2018/132876, Novel glycine transport inhibitors for the treatment of pain, University of Sydney and University of Technology, Sydney, 26 July 2018
- WO/2018/132874, Method of preventing an immune response with Alpha-1 anti-trypsin, CSL Ltd, 26 July 2018
- WO/2018/128587, Mutant SMCHD1 for therapy, Walter and Eliza Hall Institute of Medical Research, Insitut National de aa Santé et de la Recherche Médicale (France) and Universitätsmedizin Göttingen (Germany), 12 July 2018
- WO/2018/112557, Methods and compositions for purification or isolation of microvesicles and exosomes, Altnia Operations Pty Ltd, 28 June 2018
- WO/2018/112549, Antibodies to Il-37, Monash University and Hudson Institute of Medical Research, 28 June 2018
- WO/2018/112545, Inhibitors of SOX18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases, University of Queensland, 28 June 2018
- WO/2018/112544, Biofilm disrupting composition for use on chronic wounds, Whiteley Corporation Pty Ltd and University of Sydney, 28 June 2018
- WO/2018/112541, Methods for enhancing vascular density, University of New South Wales, 28 June 2018
- WO/2018/112515, Terminalia ferdinandiana leaf extract and products containing extract of Terminalia ferdinandiana leaf, Rising Phoenix Industries Pty Ltd, 28 June 2018
- WO/2018/112511, Biofilm disrupting composition, Whiteley Corporation Pty Ltd and University of Sydney, 28 June 2018
- WO/2018/107246, Improving selective internal radiation therapy, Australian National University, 21 June 2018
- WO/2018/107244, Composition and uses thereof, Progen PG500 Series Pty Ltd, 21 June 2018
- WO/2018/107241, Treatment of iron disorders, University of Sydney, 21 June 2018
- WO/2018/107236, Novel compounds as anti-mycobacterials, University of Sydney, 21 June 2018
- WO/2018/107228, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, Benitec Biopharma, 21 June 2018
- WO/2018/107226, Methods of treating ocular disorders, Beta Therapeutics Pty Ltd, 21 June 2018
- WO/2018/107216, Non-peptide oxytocin receptor agonists, University of Sydney, 21 June 2018
- WO/2018/107205, Radiolabelled material for targeted administration, Australian National University, 21 June 2018
- WO/2018/107201, Heparanase inhibitors and use thereof, Beta Therapeutics Pty Ltd, 21 June 2018
- WO/2018/107200, Heparanase inhibitors and use thereof, Beta Therapeutics Pty Ltd, 21 June 2018
- WO/2018/102890, Visualization constructs, University of Queensland, 14 June 2018
- WO/2018/102889, Glycopeptide antibiotic constructs, University of Queensland, 14 June 2018
- WO/2018/102885, Modulators of nicotinic acetylcholine receptors and uses thereof, Bionomics, 14 June 2018
- WO/2018/102857, Determining cancer responsiveness to treatment, Queensland University of Technology, 14 June 2018
- WO/2018/102854, Treatment of obesity and eating disorders, St Vincent's Hospital Sydney, 14 June 2018
- WO/2018/102849, Photodynamic therapeutic compounds and photodynamic methods of treatment, Salt and Light Pharmaceuticals Pty Ltd, 14 June 2018
- WO/2018/098534, Methods of treating cancer and reagents thereof, Garvan Institute of Medical Research, 7 June 2018
- WO/2018/098519, Arsenic compositions, Eupharma Pty Ltd, 7 June 2018
- WO/2018/094470, Method and agents for reducing general anaesthetic induced neuroexcitation, University of Queensland, 31 May 2018
- WO/2018/094460, Anti-CD300f antibody and uses thereof, Dendrocyte Biotech Pty Ltd, 31 May 2018
- WO/2018/091967, Compositions for the treatment of hypertension, George Institute for Global Health, 24 May 2018
- WO/2018/090100, Methods and products for reducing resistance to anti-parasitic agents, Resurrect Refugia Pty Ltd, 24 May 2018
- WO/2018/090096, Taste masking product, University of Western Australia, 24 May 2018
- WO/2018/090073, Nanospheres for cosmetic and pharmaceutical use, Ultraceuticals Pty Ltd, 24 May 2018
- WO/2018/089912, Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease, Amgen with five inventors including Stephen Nicholls, 17 May 2018
- WO/2018/085890, Reconstituted High Density Lipoprotein treatment of myocardial infarction, CSL Ltd, 17 May 2018
- WO/2018/085888, Subtilase Cytotoxin B subunit mutant, Griffith University and University of Adelaide, 17 May 2018
- WO/2018/085886, Livestock supplement and use thereof, Charles Sturt University, 17 May 2018
- WO/2018/085877, A method of treatment, University of Melbourne, 17 May 2018
- WO/2018/085171, Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors, Merck & Co. and ten inventors including Andrew Harvey, 11 May 2018
- WO/2018/085170, Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors, Merck & Co. and six inventors including Andrew Harvey, 11 May 2018
- WO/2018/081878, Modulation of protein accumulation and uses therefor, Macquarie University, 11 May 2018
- WO/2018/081869, Antimicrobial compounds, University of New South Wales, 11 May 2018
- WO/2018/081863, 6-substituted derivatives of hexamethylene amiloride as inhibitors of uPA and uses thereof, University of Wollongong, 11 May 2018
- WO/2018/081862, Modified antibacterial compositions and methods, University of Melbourne, 11 May 2018
- WO/2018/081861, Antimicrobial composition combinations comprising star shaped peptide polymers, University of Melbourne, 11 May 2018
- WO/2018/081860, Formulations for radiotherapy and diagnostic imaging, Clarity Pharmaceuticals Pty Ltd, 11 May 2018
- WO/2018/081858, Improved analogues of Desferrioxamine B and their uses, University of Sydney, 11 May 2018
- WO/2018/081845, Antibacterial compositions and methods, University of Melbourne, 11 May 2018
- WO/2018/076074, Mucosal active agent delivery, SUDA Pharmaceuticals, 3 May 2018
- WO/2018/076060, Improved generation of muscle lineage cells and therapeutic uses thereof, Genea Biocells, 3 May 2018
- WO/2018/076049, Immunogenic protein and method of use, University of Queensland, 3 May 2018
- WO/2018/071988, Oral medication formulations, Grunbiotics Pty Ltd, 26 April 2018
- WO/2018/071975, Cell population seeding in dermal matrices for endocrine disorder management, Beta Cell Technologies Pty Ltd, 26 April 2018
- WO/2018/071967, Cell associated scaffolds for delivery of agents, Australian Foundation for Diabetes Research, 26 April 2018
- WO/2018/071959, Cytotoxic particles, Biosceptre, 26 April 2018
- WO/2018/068090, Therapeutic agents and methods of producing same, Glycan Biosciences (US) with Deirdre Coombe of Curtin University, 19 April 2018
- WO/2018/065923, Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same, EnGeneIC, 12 April 2018
- WO/2018/064718, Peptide libraries and methods of use, Queensland Institute of Medical Research, 12 April 2018
- WO/2018/064498, Methods of treating epilepsy and related neurological conditions, Pairnomix, LLC (USA) with eight inventors including Steven Petrou, 5 April 2018
- WO/2018/058199, Dental caries status disclosing solutions, R.M Creighton Dental Pty Ltd, 5 April 2018
- WO/2018/058177, Assembled glycoproteins, Macfarlane Burnet Institute for Medical Research and Public Health, 5 April 2018
- WO/2018/053601, Method for preparing a lipid bubble, University of Queensland, 29 March 2018
- WO/2018/053597, Coagulation factor binding proteins and uses thereof, CSL Ltd, 29 March 2018
- WO/2018/053595, Methods for improving cerebrovascular function and cognition in peri- and post-menopausal women, University of Newcastle, 29 March 2018
- WO/2018/053588, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 29 March 2018
- WO/2018/053587, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 29 March 2018
- WO/2018/053578, Isotopic compositions, Ambrosis Kambouris, 29 March 2018
- WO/2018/049474, Antibody and checkpoint inhibitor combination therapy, Bionomics, 22 March 2018
- WO/2018/049471, Reagents for producing T-cells with non-functional T-cell receptors (TCRs) compositions comprising same and use thereof, Benitec Biopharma, 22 March 2018
- WO/2018/049468, A method of purifying metal oxide particles and uses thereof, RMIT University, 22 March 2018
- WO/2018/049459, Vaccine comprising drug and parasite administration, Griffith University, 22 March 2018
- WO/2018/049165, Immunotherapy for polyomaviruses, Atara Biotherapeutics (US) and QIMR Berghofer Medical Research Institute, 15 March 2018
- WO/2018/047157, Wound covering with haemostatic action and the method of its creation, Alexander Plotkin (Israel) and Dmitri Menglet, 15 March 2018
- WO/2018/045424, Medicinal use of serrulatane diterpenes, University of Sydney, 15 March 2018
- WO/2018/045422, Lysine specific histone demethylase-1 inhibitors and uses therefor, University of Canberra, 15 March 2018
- WO/2018/045417, A clinical management protocol, Graeme Southwick, 15 March 2018
- WO/2018/039748, Wound healing peptide, James Cook University, 8 March 2018
- WO/2018/032057, Viral vaccines, Sementis, 22 February 2018
- WO/2018/027278, Omega-3 compositions and methods relating thereto, Pharmako Biotechnologies Pty Ltd, 15 February 2018
- WO/2018/027274, Metabolites for treatment and prevention of autoimmune disease, Monash University, 15 February 2018
- WO/2018/027252, Immune-modulating compounds, QIMR Berghofer Medical Research Institute, 15 February 2018
- WO/2018/023170, A method of treatment, Hudson Institute of Medical Research, 8 February 2018
- WO/2018/023166, Cannabis composition, Zelda Therapeutics, 8 February 2018
- WO/2018/023164, Cannabis composition, Zelda Therapeutics, 8 February 2018
- WO/2018/023163, Cannabis composition, Zelda Therapeutics, 8 February 2018
- WO/2018/023151, Composition comprising Duddingtonia flagrans, International Animal Health Products Pty Ltd, 8 February 2018
- WO/2018/018097, Method of treatment, QBiotics, 1 February 2018
- WO/2018/018091, Compositions for the treatment of pulmonary fibrosis, Vectus Biosystems, 1 February 2018
- WO/2018/018082, Immunostimulatory compositions and uses therefor, Australian National University, 1 February 2018
- WO/2018/018077, Methods of treating breast cancer and reagents therefor, Garvan Institute of Medical Research and Peter MacCallum Cancer Centre, 1 February 2018
- WO/2018/018073, Methods of treating cancer, Ascend Biopharmaceuticals, 1 February 2018
- WO/2018/017719, Methods for enhancing utrophin production via inhibition of microRNA, University of Pennsylvania and Murdoch University, 25 January 2018
- WO/2018/014091, Insulin analogs, University of Utah, Walter and Eliza Hall Institute of Medical Research and La Trobe University, 25 January 2018
- WO/2018/014078, Iridium complexes for cellular imaging, University of South Australia and Curtin University, 25 January 2018
- WO/2018/014068, Attenuated Type I IFN CD47 combination therapy, Teva Pharmaceuticals Australia Pty Ltd, 25 January 2018
- WO/2018/014067, Anti-CD47 combination therapy, Teva Pharmaceuticals Australia Pty Ltd, 25 January 2018
- WO/2018/009972, Chimeric Antigen Receptor modified T cells, Peter MacCallum Cancer Institute, 18 January 2018
- WO/2018/009547, Diagnosing COL6-related disorders and methods for treating same, The US Department of Health and Human Services with three scientists from Massachusetts General Hospital and Professor Steve Wilton of Murdoch University
- WO/2018/004433, Nemertea-derived bioactive compounds, Five Swedish scientists including Johan Rosengren of the University of Queensland, 4 January 2018
- WO/2018/000047, Method of treating immunoglobulin light chain amyloidosis, Prana Biotechnology, 4 January 2018
- WO/2018/000028, Novel antibiotics, Boulos & Cooper Pharmaceuticals Pty Ltd, 4 January 2018
- WO/2018/000013, Aesthetically elegant sexual lubricants and massage gels, Ansell, 4 January 2018
- WO/2017/221158, Anti-parasitic compositions and methods, University of Canberra, 28 December 2017
- WO/2017/220369, Antibodies against MAC-1, Baker IDI Heart and Diabetes Institute and Albert-Ludwigs-Universität Freiburg, 28 December 2017
- WO/2017/219087, New thiosemicarbazone compounds and analogues thereof, University of Sydney, 28 December 2017
- WO/2017/219086, Anti-ageing compounds, University of Sydney, 28 December 2017
- WO/2017/219083, Activators of HIV latency, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, 28 December 2017
- WO/2017/219081, Spider venom peptides and methods of use for modulating sodium channels, University of Queensland, 28 December 2017
- WO/2017/219080, Treatment for myopia, University of Newcastle, 28 December 2017
- WO/2017/219078, Allosteric regulation of haemostatic activity, University of Sydney, 28 December 2017
- WO/2017/214683, Methods and compositions for the treatment or prophylaxis of an ectoparasitic infestation, Gretals Australia Pty Ltd, 21 December 2017
- WO/2017/214681, Agents and methods for the diagnosis and treatment of diseases associated with extracellular matrix turnover, Baker IDI Heart and Diabetes Institute, 21 December 2017
- WO/2017/214680, Adamantane compounds, University of Sydney, 21 December 2017
- WO/2017/210749, Methods and products for treating autoimmune diseases, University of Adelaide, 14 December 2017
- WO/2017/210735, Methods of treating neuroblastoma and reagents therefor, Garvan Institute of Medical Research and Peter MacCallum Cancer Institute, 14 December 2017
- WO/2017/210726, Peptides for hair growth, Clinical Stem Cells Pty Ltd, 14 December 2017
- WO/2017/205939, Vitamin D formulations and therapeutic uses thereof, Indigo Ridge Pty Ltd, 7 December 2017
- WO/2017/205901, Hydrophilic polymer conjugate with multiple antiviral agents for treating a viral infection, Commonwealth Scientific and Industrial Research Organisation, 7 December 2017
- WO/2017/205895, Skin care formulation, Embryogenesis Pty Ltd, 7 December 2017
- WO/2017/203397, Inner ear plug, Cochlear Ltd, 30 November 2017
- WO/2017/203368, Methods of treating autoimmune disease using allogeneic T cells, QIMR Berghofer Medical Research Institute, 30 November 2017
- WO/2017/203362, Immune checkpoint inhibitors and cytotoxic T cells for the treatment of cancer, QIMR Berghofer Medical Research Institute, 30 November 2017
- WO/2017/201585, Modulators of DUX4 for regulation of muscle function, Genea Biocells, 30 November 2017
- WO/2017/201581, Non-toxic iron chelators with neuroprotective potential, University of Sydney, 30 November 2017
- WO/2017/201579, Arthrogenic alphavirus vaccine, Griffith University, 30 November 2017
- WO/2017/201573, A method of classification and treatment, Peter MacCallum Cancer Institute, 30 November 2017
- WO/2017/201563, Treatment of alphavirus-induced inflammation, Griffith University, 30 November 2017
- WO/2017/197463, Treatment of pain, Monash University and Queens University at Kingston (Canada), 23 November 2017
- WO/2017/197453, Microencapsulated omega-3 polyunsaturated fatty acid glyceride compositions and processes for preparing the same, Deakin University, 23 November 2017
- WO/2017/194912, Treatment of complement-mediated disorders, University of Cambridge (UK) and Sydney Children's Hospital Network, 16 November 2017
- WO/2017/193169, Protection of plant extracts and compounds from degradation, Medlab Clinical Ltd, 16 November 2017
- WO/2017/193161, Agent delivery system, WRS Therapeutics Pty Ltd, 16 November 2017
- WO/2017/192699, Adeno-Associated Virus polynucleotides, polypeptides and virions, Children's Medical Research Institute, Sydney Children's Hospital Network and US Department of Health and Human Services, 9 November 2017
- WO/2017/190197, Reagents for treatment of Hepatitis B Virus (HBV) infection and use thereof, Benitec Biopharma Ltd, 9 November 2017
- WO/2017/190193, Method of prophylaxis of Zika virus infection, Starpharma Ltd, 9 November 2017
- WO/2017/190183, Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith, T & A Pharma Pty Ltd, 9 November 2017
- WO/2017/185142, Method for preventing and/or treating atrial fibrillation, University of Adelaide, 2 November 2017
- WO/2017/185123, Veterinary composition, Alan Thompson, 2 November 2017
New Zealand applications
Here are the 17 PCT patent applications relevant to New Zealand's Life Sciences sector that have published since 2 November 2017, for a publication rate of 0.3 applications per week:
- WO/2018/199777, Methods of treatment and novel constructs, University of Auckland, 1 November 2018
- WO/2018/185735, Anti-microbial combination, Victoria University of Wellington, 11 October 2018
- WO/2018/174725, Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses, Victoria University of Wellington and University of Liverpool, 27 September 2018
- WO/2018/160076, FGFR kinase inhibitors and pharmaceutical uses, University of Auckland and Guangzhou Institute of Biomedicine and Health, 7 September 2018
- WO/2018/143826, Cancer therapeutic, Gillies McIndoe Research Institute, 9 August 2018
- WO/2018/117868, Method of processing shellfish and resulting compositions, Sanford Ltd, 28 June 2018
- WO/2018/117867, Bioactive mussel compositions and/or extracts, Sanford Ltd, 28 June 2018
- WO/2018/116146, Compositions derived from Galenia africana and methods of use for cancer treatment, Biopharm NZ Ltd, 28 June 2018
- WO/2018/063008, Beta-caseins and gut microbiota, A2 Milk Company, 5 April 2018
- WO/2018/038623, Improvements in parasite treatments, Donaghys, 1 March 2018
- WO/2018/035706, Traditional Chinese medicine preparation for atopic dermatitis, preparation method therefor and use thereof, Jian Tan, 1 March 2018
- WO/2018/020473, Dairy product and process, Fonterra Co-Operative Group and five inventors including Bing Wang of Charles Sturt University, 1 February 2018
- WO/2017/217868, Water-dispersible propolis composition, Andrew Lavrent, 21 December 2017
- WO/2017/213524, Treatment of neurodegenerative disorders, Garth Cooper, 14 December 2017
- WO/2017/200396, Antibacterial compositions, David Ackerley and Janine Copp, 23 November 2017
- WO/2017/200391, Compositions comprising L-Theanine, proanthocyanidin/s and a catechin and uses thereof, Alphagen NZ, 23 November 2017
- WO/2017/192620, Novel peptides and peptidomimetics, University of Auckland and Ocunexus Therapeutics, 9 November 2017
Copyright © 2018 NDF Research